Accelerated Approvals Face More Pressure To Finish Trials; Midodrine A Concern
Executive Summary
Midodrine hydrochloride, which seemingly takes the gold for most outstanding post-marketing studies among Subpart H approvals, soon may be pulled from the market, FDA warns application holders in an Aug. 18 letter
You may also be interested in...
FDA Begins Withdrawal For Midodrine Three Years After It First Threatened To End Approval
With no confirmatory studies in sight, agency takes action 14 years after accelerated approval of Shire's hypotension drug ProAmatine, which has since gone generic.
Accelerated “De-proval”? FDA May Be Ready To Withdraw Subpart H Drug
FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.